What is Zyprexa?

Zyprexa is a drug preparation that contains the active substance olanzapine. It is available in the form of different tablets (2.5, 5, 7.5, 10, 15 and 20 mg) and powder for solution for injection.
To what purpose, the preparation Zyprexa?

Preparation Zyprexa is used to treat schizophrenia. It is a mental disorder, as reflected in a number of symptoms, including disorganization of thought and speech, omamami (hearing or seeing things that do not exist), suspicion, yprexa delusions (mistaken beliefs). Preparation Zyprexa is also effective in maintaining improvement in patients who had a reaction to the initial course of treatment.
Preparation Zyprexa is also used in the treatment of moderate or severe manic episodes (extremely elevated mood). It can also be used to prevent relapse (when the symptoms reappear) of these episodes in patients with unipolar illness (mental illness, which in turn are periods of elevated mood and depression), which occurred in response zprexa to an initial course of treatment).
Preparation of Zyprexa is usually oral, but can also perform the injection in order to obtain a rapid control of arousal, or behavior disorders in patients with schizophrenia or manic episode, when oral medication is not accepting. The medicine is available only on prescription.
How to use the product Zyprexa?

The recommended starting dose of tablets is dependent on Zyprexa choroby.W treatment of schizophrenia and the prevention of manic episodes, the 10 zyrexa mg / day, and in the treatment of manic episodes, the 15 mg / day, unless the product is used in combination with other drugs, in which case The starting dose may be 10 mg / day. Dose is adjusted according to that seen in patient response to therapy and tolerance of treatment, the typical dosage range is from 5 to 20 mg / day.
The usual dose for the use of injection is 10 mg zypexa in a single intramuscular injection. If necessary, after 2 hours, you can perform a further injection of 5 or 10 mg. Lower doses may be necessary in patients over the age of 65 years (5 mg / day in the case of tablets, 2.5 to 5 mg for injection), as well as in patients with hepatic impairment or renal failure (5 mg / day, both in the case of tablets and injections).
In all cases the zyprxa maximum dose of Zyprexa, which can be given throughout the day in the form of tablets or injections, is 20 mg.
How does Zyprexa?

The active substance in the preparation Zyprexa, olanzapine, is a medicine antipscychotic. It is determined atypowym drug przeciwpsychotycznym because it differs from the older drugs przeciwpsychotycznych which are available from the 50-years. Its exact mechanism of action is unknown, but it joins a number of different receptors on the surface of nerve cells zyprea in the brain. This results in an interruption of the signals transmitted between brain cells by neurotransmitters - chemicals that allow nerve cells communicate. It is believed that the beneficial effect of olanzapine is associated mainly with blocking receptors for the neurotransmitters 5-hydroksytryptaminy (serotonin) and dopamine. Due to the fact that these neurotransmitters play a role in schizophrenia and unipolar illness, olanzapine helps in the normalization of brain activity, reducing the symptoms of these diseases.
The zyprex preparation as Zyprexa?

Zyprexa tablets was studied in the treatment of schizophrenia in about 3 000 patients in whom the effectiveness of their performance was compared with a placebo (inactive treatment) or haloperidol (another drug przeciwpsychotycznego). All four studies lasting 6 weeks, but patients received medication for a period of one year or longer.
In the treatment of acute manic episodes in patients with unipolar disease Zyprexa tablets compared with placebo, haloperidolem or walproinianem (another drug used yzprexa in manic episodes) in five studies, including one study in which patients received other drugs. Zyprexa tablets was studied in 1 162 patients in the prevention of manic episodes. Their effectiveness was compared to the performance of lithium or placebo (another drug used in unipolar illness).
The injection was studied in 581 patients with schizophrenia (compared with placebo or haloperidolem injections) and 228 patients with mania (as compared with placebo injections or lorazepamu (another drug used zpyrexa for manic episodes).
In all studies, the effectiveness of Zyprexa was assessed on the basis of different scales of assessment of symptoms.
What benefit has been observed in studies Zyprexa?

In all studies, preparation Zyprexa, whether in the form of tablets and injections, reduced the symptoms better than placebo. Zyprexa tablets were at least as effective as medication with which they were compared in the treatment of schizophrenia (haloperidol) in treating moderate or severe manic episodes (haloperidol, walproinian) zyrpexa and in preventing relapse in patients with unipolar illness (lit). Also been shown that injections are more effective than that of lorazepamu (in a relatively low dose) in patients with mania, as well as effective as haloperidol in schizophrenia.
What is the risk associated with the use of Zyprexa?

The most common side effects associated with treatment with Zyprexa (observed more than 1 patient at 10) are as follows: drowsiness, weight gain and elevated levels of prolactin zyperxa (a hormone). The full list of side effects reported with Zyprexa, see the Package Leaflet.
Zyprexa preparation should not be given to persons who may be hypersensitive (allergic) to olanzapine or any other ingredients. Zyprexa preparation should not be given to patients at risk of glaucoma with a narrow angle by percolation (increased pressure in the eye).
Why preparation approved Zyprexa?

The Committee for Medicinal Products for Human Use (CHMP) decided that the benefits from the use outweigh zyprxea the risks of Zyprexa to treat schizophrenia, including the maintenance of clinical improvement during continuation therapy in patients who had an initial response to therapy in the treatment of moderate or severe manic episodes, and in preventing relapse in patients with unipolar illness, and in the case of injections in the rapid control of arousal, or behavior disorders in patients with schizophrenia or manic episode, when oral therapy is not appropriate. The Committee recommended the zypreax granting of an authorization for marketing of Zyprexa.